Sign in

    Kenneth Cacciatore

    Managing Director and Senior Research Analyst at Cowen and Company

    Kenneth Cacciatore is a Managing Director and Senior Research Analyst at TD Cowen, specializing in healthcare and pharmaceutical sector research with a focus on companies such as Jazz Pharmaceuticals, Medicis Pharmaceutical, Kythera, Neuroderm, and TherapeuticsMD. He covers over 50 healthcare stocks and has achieved notable success including a 100% success rate with several companies and top single-rating returns exceeding +230%. Cacciatore joined Cowen in 2000 and has contributed significantly to Cowen's pharmaceutical research team, often shaping market forecasts and valuations. He holds recognized professional credentials as a senior analyst, and his research is regularly cited in the industry.

    Kenneth Cacciatore's questions to Biohaven (BHVN) leadership

    Kenneth Cacciatore's questions to Biohaven (BHVN) leadership • Q1 2021

    Question

    Kenneth Cacciatore of Cowen and Company asked about the status of FDA interactions for NURTEC ODT's prevention indication and the anticipated impact on sampling and gross-to-net (GTN) upon its approval.

    Answer

    CEO Vladimir Coric confirmed they are in appropriate discussions with the FDA but could not provide specifics. He and CCO BJ Jones clarified that since the dose and packaging are identical for both acute and preventive use, they do not foresee major changes to their sampling strategy or a significant impact on GTN, noting the efficiency of a single marketing message.

    Ask Fintool Equity Research AI